7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,368.98

+826.80

+1.08%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

Optimi Health Corp. (OPTH)

2.4100 -0.1900 (-7.31%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for OPTH

Chart Range Bar

Interval:

In partnership with ChartIQ

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia

Optimi Health to Present at the ThinkEquity Conference

Optimi Health to Present at the ThinkEquity Conference

Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Optimi Health Establishes $100 Million Equity Facility as Psychedelic Commercialisation Advances

Mobilize your Website

View Site in Mobile | Classic

Share by: